


## CURRICULUM VITAE

  
7/7/0

Name: Ricardo Antonio Tan, M.D.

Office: California Allergy and Asthma Medical Group, Inc.  
11645 Wilshire Blvd., Suite 1155  
Los Angeles, CA 90025  
(310)966-9022  
Fax (310)966-9042

Antelope Valley Allergy Medical Group  
41230 11th Street West, Suite A  
Palmdale, CA 93551  
(661)266-3322  
Fax (661)266-3766

Date of Birth: May 2, 1962

Citizenship: United States

Licensure: California

Hospital affiliations: Santa Monica-UCLA Medical Center  
Santa Monica, CA

St. John's Medical Center  
Santa Monica, CA

Los Angeles Metropolitan Hospital  
Los Angeles, CA

### Education

College: University of the Philippines  
Quezon City, Philippines  
Bachelor of Science in Zoology, April 1982

Medical School: University of the Philippines  
Manila, Philippines  
Doctor of Medicine, April 1986

Internship: Philippine General Hospital  
University of the Philippines Health Sciences Center  
Manila, Philippines  
May 1986 - April 1987

Residency: Internal Medicine  
Mercy Hospital of Buffalo  
State University of New York at Buffalo Health Consortium  
Buffalo, NY  
June 1988 - June 1991

Fellowship: Division of Clinical Immunology and Allergy  
UCLA Medical Center  
Los Angeles, CA  
July 1993 - December 1995

Positions Held

Chief Resident, Internal Medicine  
Mercy Hospital of Buffalo  
Buffalo, NY  
June 1990 - June 1991

Captain, US Air Force Medical Corps  
Chief, Internal Medicine  
Course Director, Advanced Cardiac Life Support  
Member, Formulary Committee  
47th Medical Squadron Hospital, Laughlin Air Force Base  
Del Rio, TX  
August 1991 - June 1993

Research Physician  
Allergy Research Foundation, Inc.  
11620 Wilshire Blvd., Suite 210  
Los Angeles, CA  
May 1995 - June 1996

Member, International Committee  
American College of Allergy, Asthma & Immunology  
2001 to 2003

Member, Public Education Committee  
American College of Allergy, Asthma & Immunology  
2000 to 2003

Member-at-large, Executive Committee  
California Society of Allergy, Asthma & Immunology  
August 2000 to August 2004

Vice-President  
International Association of Filipino Allergists and Immunologists  
January 2004 to present

Camp Physician  
Asthma Camp for Asthmatic Children  
Sponsored by Asthma and Allergy Foundation of America (AAFA)  
Big Bear Lake , CA  
July 2001 to present

Lecturer  
Core Curriculum Lecture Series for Allergy/Immunology Fellows  
David Geffen School of Medicine at UCLA  
2003 to present

Peer Reviewer  
Annals of Allergy, Asthma & Immunology  
2001 to present

Peer Reviewer  
Mayo Clinic Proceedings  
2001 to present

Peer Reviewer  
Drug Safety  
2003 to present

#### Certifications

ECFMG, April 4, 1988 ( Certificate No. 4177952 )  
Federal Licensure Examination, June 1988  
American Board of Internal Medicine, September 25, 1991 ( Certificate No. 136198 )  
American Board of Allergy and Immunology , August 11, 1997 ( Certificate No. 4233 )  
Certified Clinical Investigator , DIA Center for Career & Professional Development, May 1, 2004

#### **RESEARCH EXPERIENCE:**

Principal Investigator:  
Multicenter Clinical Trials

1. "A randomized, double-blind, double dummy, parallel group, 12 week comparative trial of salmeterol/fluticasone propionate combination product 50/100 mcg BID via the diskus inhaler versus oral montelukast 10 mg OD in adolescents and adults with persistent asthma" 2000
2. "A randomized, double-blind, parallel group, comparative trial of salmeterol/fluticasone propionate combination product 50/100 mcg diskus inhaler BID vs fluticasone propionate 250 mcg diskus inhaler BID in adolescents and adults with moderate persistent asthma."2000
3. " A multicenter, randomized, controlled, open-label study to evaluate the safety of Omalizumab in moderate to severe persistent asthma subjects already treated with other therapies ( ALTO )." 2001
4. " A multicenter, randomized, double-blind, double-dummy, parallel group, 8 week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with COPD" 2001
5. " Chronic-dose comparison of the efficacy and safety of albuterol-HFA-MDI ( Salamol™ ), albuterol-HFA-BOI ( Salamol Easibreathe™ ) and Proventil HFA™ in mild-to-moderate asthmatics." 2001.

6. "A multicenter, randomized, double-blind, double-dummy, parallel group, 16 week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol discus combination product 100/50 mcg BID, fluticasone propionate diskus 100 mcg BID, or oral montelukast 10 mg QD" 2001
6. "Dose-ranging study of RO27-2441 in patients with persistent asthma not treated with inhaled corticosteroids." 2002
7. "A randomized, multicenter, placebo-controlled parallel group study of 4 months duration per patient to evaluate the safety and efficacy of treatment with 24 mcg bid and 12 mcg bid formoterol, double-blind, and 12 mcg bid formoterol with additional on-demand formoterol doses, open-label, in adolescent and adult patients with persistent stable asthma." 2002
8. "A multicenter, double-blind, randomized, parallel study comparing the efficacy and safety of Fexofenadine 120 mg BID, Fexofenadine 120 mg BID, Fexofenadine 240 mg QD and placebo in subjects with perennial allergic rhinitis." 2003
9. "A multicenter, randomized, double-blind, double-dummy, parallel group, 42-week comparison of asthma control in hyperresponsive adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS combination product BID or fluticasone propionate DISKUS BID." 2003-2004
10. "A twelve-week, randomized, double-blind, double-dummy, placebo and active controlled study of Symbicort™ pMDI administered once daily in adults and adolescents with asthma – STEM" 2003-2004
11. "A twelve-week, randomized, double-blind, double-dummy, active-controlled study of Symbicort™ pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma – SPROUT" 2003-2004
12. "A randomized, partly blinded, multicenter, parallel study comparing the efficacy and safety of PULMICORT RESPULES™ ( budesonide inhalation suspension) at 0.5 mg QD, 1.0 mg QD, 1.0 mg BID, 2.0 mg BID and PULMICORT TURBUHALER® ( budesonide) at 400 mcg BID in adolescents ( 12 years of age and older) and adults with moderate and severe asthma. 2004-2005.
13. "A randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial designed to assess the efficacy and safety of ciclesonide applied as a nasal spray at three dose levels ( 100 mg, 200 mg, 25 mg, once daily) in the treatment of perennial allergic rhinitis ( PAR) in patients 6-11 years of age." -2004
14. "A 6-week randomized, double-blind, placebo-controlled, multicenter study, to assess the efficacy and safety of oral tegaserod (6 mg bid) and placebo in female patients with dyspepsia. CHTF919D2301." 2004-2006.
15. "A 1 year , randomized, double blind, parallel-group, placebo-controlled, multicenter evaluation of efficacy, safety, pharmacokinetics and pharmacodynamics of omalizumab in children ( 6-<12 years ) in moderate-severe , persistent, inadequately controlled allergic asthma." 2005
16. " Safety and efficacy evaluation of two doses of HFA-propelled beclomethasone dipropionate (QVAR™) versus placebo by breath operated and metered dose inhalers in mild to moderate asthmatic children. IXR-302-25-197" 2005
17. "A double-blind, randomized, parallel-group, multicenter clinical study to compare the efficacy and tolerability of tiotropium bromide alone vs. the co-administration of tiotropium bromide and formoterol fumarate in subjects with COPD. P04272-48" 2005-2006.

18. "A multicenter, randomized, double-blind, parallel-group, 52-week comparison of asthma control and measures of airway inflammation in subjects of African descent receiving fluticasone propionate/ salmeterol 100/50 DISKUS BID or fluticasone propionate 100 mcg DISKUS BID alone. SFA103153." 2006
19. "A multicenter, randomized, double-blind, triple-dummy, placebo-controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus montelukast 10 mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving ADVAIR DISKUS 100/50 mcg BID or Placebo BID. ADA 103578" 2006
20. "A Phase IIIb multicenter randomized, double-blind, placebo-controlled study of Xolair™ in subjects with moderate to severe persistent asthma who are inadequately controlled with Advair 500/50 bid, Q3662G EXTRA study". 2006
21. "A 26-week, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the effect of Xolair (omalizumab) on improving the tolerability of specific immunotherapy in patients with persistent allergic asthma. IGE025A, US23." 2006
22. "A Phase III multicenter study to demonstrate the sensitivity and specificity of Aridol(Mannitol) challenge as compared to methacholine challenge to predict bronchial hyperresponsiveness as manifested by a positive exercise challenge in subjects presenting with signs and symptoms suggestive of asthma but without a definitive diagnosis. DPM-A-305." 2006
23. "A placebo-controlled study of the effects of pleconaril nasal spray on common cold symptoms and asthma exacerbations following rhinovirus exposure". 2006
24. "Effect of roflumilast on exacerbation rate in patients with COPD. A 52-week, double-blind study with 500 mcg roflumilast once daily versus placebo. BY217/M2-124" 2006
25. "A comparative study of the efficacy and tolerability of maintenance treatment of patients with mild/moderate persistent asthma with Asmanex Twisthaler 220 mcg QD PM versus "Asmanex" placebo QD PM ( ASTER). P04654" 2006



**The Medical Board of California**  
2005 Evergreen Street, Suite 1200  
Sacramento, CA 95815



**PHYSICIAN AND SURGEON**  
CERTIFICATE NO    A52236    EXPIRATION    05/31/2011  
**RICARDO ANTONIO TAN**  
5219 CEDROS AVE  
SHERMAN OAKS CA 91411

ORIGINAL  
ISSUANCE DATE  
08/05/1993

RECEIPT NO  
09200062